Protocol # ADMA-001: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial Evaluating the Safety and Efficacy of RI-001 in Medically Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV

Sponsor: ADMA Biologics, Inc.

Location(s): United States


RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-001 for the prevention of lower respiratory tract infections in immunocompromised patients identified as being infected with RSV in the upper respiratory tract.